• Veru to progress Covid-19 drug into Phase III study pharmaceutical-technology
    March 03, 2021
    Veru is set to advance its drug VERU-111 into a Phase III registration clinical study on hospitalised high-risk Covid-19 patients for obtaining clinically meaningful benefits in the Phase II clinical trial.
  • Veru reports positive data from Phase II Covid-19 drug trial pharmaceutical-technology
    February 10, 2021
    Veru has reported positive efficacy and safety results from Phase II clinical trial of an oral drug, VERU-111, in hospitalised Covid-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).
PharmaSources Customer Service